Sherry Zhou, MD
Endocrinology, Diabetes & Metabolism · Saint Joseph, MONPI 1740211689
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $13,896 of the $15,848 with a category attached, or 87.7%. It is spread thinly across 51 manufacturers, the largest accounting for just 8.7% — the pattern of someone who eats at a lot of different presentations.
Across 708 payments — averaging $22.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$1K
- Mannkind Corporation$1K
- AstraZeneca$1K
- Novo Nordisk$1K
- Lilly USA, LLC$1K
- Abbott$1K
- plus $8K from 45 others
What the payments were for
- Consulting fees$8505%
- Speaking & faculty fees$1,0276%
- Food & beverage$13,89688%
- Education$160%
- Gifts$590%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AFREZZA$850
- SOLIQUA 100/33$830
- CeQur Simplicity$685
- Minimed 530G$363
- MINIMED 780G$319
- RYBELSUS$232
- FARXIGA$110
- Wegovy$105
How this compares
$15,848 in reported general payments places this provider in the 80th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.
See all endocrinology, diabetes & metabolism providers in Missouri →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 315 | $418,450 |
| FarxigaDapagliflozin Propanediol | 320 | $334,714 |
| Tresiba Flextouch U-200Insulin Degludec | 123 | $301,438 |
| JardianceEmpagliflozin | 250 | $292,067 |
| TrulicityDulaglutide | 155 | $212,276 |
| JanuviaSitagliptin Phosphate | 145 | $148,918 |
| MounjaroTirzepatide | 103 | $141,677 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 80 | $124,205 |
| Tresiba Flextouch U-100Insulin Degludec | 115 | $109,007 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 450 | $101,147 |
| TradjentaLinagliptin | 96 | $77,754 |
| Humalog Kwikpen U-100Insulin Lispro | 132 | $72,170 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 61 | $68,381 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 98 | $47,186 |
| Novolog FlexpenInsulin Aspart | 113 | $36,560 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Fiasp, Rybelsus, Xultophy 100-3.6, Novolog | $1,200 | $501,529399 claims |
| Boehringer IngelheimJardiance, Tradjenta, Glyxambi, Synjardy | $807 | $405,777375 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $1,179 | $377,278301 claims |
| AstraZenecaFarxiga | $1,286 | $334,714320 claims |
| MerckJanuvia, Janumet Xr, Janumet | $186 | $193,835204 claims |
| AbbVieSynthroid | $205 | $21,234246 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $196 | $12,4681,459 claims |
| Sanofi-aventis U.S. LLCLantus | $1,384 | $8,11923 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.
Other endocrinology, diabetes & metabolism in Saint Joseph
- Junping YangSaint Joseph$46K
- Ahmad Al-MubaslatSaint Joseph$35K
- Ralph DudaSpringfield$644K
- Karen Chang-ChenChesterfield$640K
- Alan RaubaJefferson City$594K
- Jerome ThurmanSaint Charles$312K
- Janet McGillSaint Louis$212K
- Megan WoodSt. Louis$207K
- Ralph OiknineChesterfield$144K
- Jonben SvobodaSpringfield$142K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.